WALTHAM, Mass.--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global technology leader in Health Sciences and Photonics, today announced the launch of a comprehensive assay development service for high-performance, highly sensitive assays in advanced cellular science and drug discovery research.
